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Abstract
Background: Completion of multiple dose vaccine schedules is crucial to ensure a protective immune response,
and maximise vaccine cost-effectiveness. While barriers and facilitators to vaccine uptake have recently been
reviewed, there is no comprehensive review of factors influencing subsequent adherence or completion, which is
key to achieving vaccine effectiveness. This study identifies and summarises the literature on factors affecting
completion of multi-dose vaccine schedules by adolescents.
Methods: Ten online databases and four websites were searched (February 2014). Studies with analysis of factors
predicting completion of multi-dose vaccines were included. Study participants within 9–19 years of age were
included in the review. The defined outcome was completion of the vaccine series within 1 year among those who
received the first dose.
Results: Overall, 6159 abstracts were screened, and 502 full texts were reviewed. Sixty one studies were eligible for
this review. All except two were set in high-income countries. Included studies evaluated human papillomavirus
vaccine, hepatitis A, hepatitis B, and varicella vaccines. Reported vaccine completion rates, among those who
initiated vaccination, ranged from 27 % to over 90 %. Minority racial or ethnic groups and inadequate health
insurance coverage were risk factors for low completion, irrespective of initiation rates. Parental healthcare seeking
behaviour was positively associated with completion. Vaccine delivery in schools was associated with higher
completion than delivery in the community or health facilities. Gender, prior healthcare use and socio-economic
status rarely remained significant risks or protective factors in multivariate analysis.
Conclusions: Almost all studies investigating factors affecting completion have been carried out in developed
countries and investigate a limited range of variables. Increased understanding of barriers to completion in
adolescents will be invaluable to future new vaccine introductions and the further development of an adolescent
health platform.
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Background
In the past decade there has been an increase in the num-
ber of new vaccines licensed worldwide [1, 2] and in the
accessible funding for vaccine introduction to low-
resource settings through the founding of Gavi, The
Vaccine Alliance, in 2000 [3]. Multi-dose vaccines in the
WHO recommended immunization schedule for adoles-
cents are listed in Table 1; WHO defines adolescence as
age 10–19 years inclusive. National vaccine schedules can
depart from WHO recommendations, e.g. 2 doses of
hepatitis A and meningococcal conjugate vaccines
(MCV4) are offered to adolescents in the USA [4].
Although recommended for administration at birth, hepa-
titis B vaccine (HBV) is routinely offered to older children
and adolescents if not previously immunised [5]. In
settings where varicella is seen as a public health priority
WHO recommends 2 doses of varicella vaccine, with the
first dose at 12–18 months and up to 4 month interval
between doses [6, 7]. The most recently licensed multi-
dose vaccines are the human papillomavirus (HPV)
vaccines. In 2014, HPV vaccine recommendations were
revised by WHO SAGE from a schedule of 3 doses [8], to
2 doses at a 6 month interval in girls less than or equal to
15 years of age [9, 10] based on evidence of non-inferior
immunogenicity [11, 12].
At present, evidence suggests multiple doses of HBV,
HPV, and varicella vaccines are needed for efficacious
protection against disease in adolescents [5, 9, 13, 14].
However; completion of the vaccine dose series, defined
as receipt of the final dose within 1 year of the first dose,
has proven challenging in some settings. Completion
rates of HPV vaccine were lower than 30 % in the first
years of introduction in the USA [15, 16]. Addressing
specific difficulties in administering vaccines to adoles-
cents will be invaluable for implementation of future
adolescent vaccines and further developing adolescent
health services.
The currently available reviews of factors influencing
completion focus solely on selected developed countries
[1, 17–19], have non-systematic searches [20, 21] or
need updating [22]. This systematic review describes fac-
tors which have been investigated for their effect on
multi-dose vaccine adherence in adolescents to aid de-
velopment of interventions to improve adherence.
Methods
Search strategy
A comprehensive set of search terms was built around:
1) childhood/adolescence; 2) vaccination/immunisation;
3) adherence/completion. Articles with at least one term
Table 1 WHO recommended vaccine schedule for adolescentsa, b. Caption: the WHO recommended schedule of vaccines for
adolescents (10–19 years of age inclusive), if not given prior to age 10 years
Recommended vaccines for all adolescents Adolescent dosage Licensed age
Tetanus, diphtheria, pertussis 3 doses Tdapa & Td Booster Infant onwards
Human papillomavirus 2 doses if ≤15 years ≥9 years
3 doses thereafter
Meningococcal conjugate MenA: 1 dose Infant onwards
MenC: 1 dose
MCV4: 1 dose
Influenza 1 dose Yearly booster ≥9 years
Hepatitis A 1 dose Infant onwards
Hepatitis B 3 dosesa Infant onwards
Measles, Mumps, Rubella 1 dosea Infant onwards
Recommended in at-risk areas Adolescent dosage Licensed age
Tick borne encephalitis 3 doses Infant onwards
Japanese encephalitis 1 dose Infant onwards
Typhoid Vi polysaccharide: 1 dose Infant onwards
Ty21a live oral vaccine: 3–4 doses
Booster 3–7 years after primary series
Cholera Dukoral, Shanchol & mORCVAX: 2 doses booster every 2nd yr ≥2 years
Rabies 3 doses Infant onwards
Varicella 2 doses ≥9–12 months
aRecommended schedule if not administered prior to age 10 years
bWorld Health Organization. WHO recommendations for routine immunization - summary tables -
http://www.who.int/immunization/policy/immunization_tables/en/ 2014
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from each topic were identified. Search terms were in-
formed by the Cochrane Child Health Group recom-
mended terms for adolescents or school children [23]
and included international spelling variations (Additional
file 1: Table S1). Multi-dose vaccines administered to ado-
lescents were identified through the Centers for Disease,
Control, and Prevention (CDC) [6, 24], and the WHO list
of prequalified vaccines [25]; however, search terms were
not limited to these vaccines.
Medline, Embase, Global Health (Ovid SP), Popline,
Web of Science, Africa Portal, Africa-wide information,
ADOLEC, Cochrane, Open Grey databases, and PATH,
Gavi, and WHO websites were searched in February
2014. No publication date restriction was set. Publica-
tions, abstracts and conference proceeding were eligible
for inclusion. All texts were collated and reviewed using
Endnote X7 (Thompson Reuters); automated and man-
ual de-duplication was performed.
Inclusion criteria
Inclusion criteria for consideration of studies were out-
lined in a protocol a-priori as per PRISMA guidelines
[26] (Table 2). The title and/or abstract of each article
were reviewed in the first instance by a single reviewer
(KG). Modelling studies, immunogenicity/efficacy trials
were excluded. Two reviewers (KG, SM/EK) screened
the abstracts. Any study including a vaccine for which
more than one dose was administered to persons 9–19
years old in a routine setting within 1 year was consid-
ered for inclusion. The WHO definition of adolescent
(10–19 years old) was widened to include 9 year olds to
include all participants in HPV vaccine studies (WHO
recommended for 9–13 year olds). Inclusion criteria
were independently applied to full texts by 2 authors
(KG, SM/EK) (Fig. 1) [26].
Data extraction
Data were extracted by 2 authors (KG, EK) into separate
forms on Microsoft Excel 2010. Article selection and
data extraction discrepancies were resolved through dis-
cussion. Data on the study population, setting, vaccine,
rates of completion and the factors investigated were ex-
tracted alongside descriptive, univariate and multivariate
results, as applicable.
Assessment of bias
An assessment of bias was recorded on the data extraction
form for each study using criteria outlined in the Cochrane
tool for assessment of bias in intervention and epidemio-
logical studies [27]. Selection bias and information bias
were assessed alongside the potential for confounding.
Data synthesis
Heterogeneity in study methods, population, context
and classification of exposure variables, led to a descrip-
tive synthesis. Groups which initiated and completed the
recommended vaccine schedule within 1 year were com-
pared to non-completers who only initiated.
Results
Of the 502 full texts reviewed (Fig. 1), 61 articles were eli-
gible for inclusion (Table 3). Included articles reported
completion rates for HPV (3-dose completion ranged
from 27 % [15] to over 90 % [28]), HBV (27 % completion
before a school mandate was introduced in California [29]
to 95 % in a school-based programme in Canada [30]),
Table 2 Study inclusion criteria. Caption: abstracts and full texts were screened independently by two authors using the following
criteria
Study definitions and
characteristics
Inclusion criteria: studies investigating factors governing adherence
Study population Any child/adolescent 9–19 years old, recruited from the community or a cohort of vaccinees, care-givers or care-
providers
Geographical setting No restriction
Vaccine Any vaccine administered to the study population in a schedule including more than one
dose within the same year
Vaccine delivery Routine vaccine delivery; studies excluded if an outbreak/campaign setting/non-routine delivery
Outcome Completion or non-completion of (or ‘adherence to’) the intended multi-dose vaccine schedule
within 1 year of follow-up
Comparison Individuals or groups who initiated vaccination (i.e. received dose 1), and completed the
vaccine series (i.e. received the final dose) within 1 year, compared to those who initiated
the vaccine series but did not receive the final dose within 1 year.
Exposure Any characteristics of individuals, communities, or programmatic or contextual factors
investigated for an association with adherence/completion
Study design Any study design with data on and analysis of factors predicting completion of a multi-dose
vaccine in routine settings
Data Some estimate of the completion rate achieved must be available
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varicella and hepatitis A vaccine (HAV). In the USA, the
two dose series of varicella vaccine was completed within
1 year in 35.9 % of adolescents and 2 doses of HAV were
completed in 40–48 % [31]. Searches returned no articles
on completion of conjugate meningococcal vaccine, des-
pite a multi-dose policy in the USA [32]. For the purposes
of this review we have focused on results from multivari-
ate analyses or qualitative findings. Data availability by
country and vaccine is displayed in Table 4.
Individual level factors
Age
The association between age and completion was inves-
tigated in 31 articles. Multivariate analyses of at least 2
age categories within the age range of 9–19 years were
conducted in 20 studies, in the USA (n = 17), Canada
[33], France [34], and Australia [35]. Age recommenda-
tions vary across countries; results must be interpreted
in context.
There is some evidence that completion rates decrease
as age of vaccine initiation increases for HPV vaccine,
HAV, and HBV [15, 31, 36–38]. In the USA, the HPV
vaccine recommended age range is between 11 and 26
years; five studies state similar results among Medicaid
enrolees, adjusting for insurance, race, region and year,
17 year olds were 0.84 times less likely to complete HPV
vaccine compared to 11 year olds (95 % CI 0.74–0.95)
[15]. Among attendees of an urban hospital, in adjusted
analyses, 14–17 year olds had 0.71 the odds of comple-
tion HPV vaccine when compared to 9–13 years olds
(95 % CI 0.59–0.98) [37].
In the USA five further studies found no association
[33, 39–43] and two studies report the converse associ-
ation, increased likelihood of completion with age be-
tween 13 and 17 years controlling for year, race, insurance
status; this perhaps reflects the perception that it was an
‘STI vaccine’ in 2007–8 [44, 45]. No association between
age and HPV vaccine completion was found in multivari-
ate analyses in Canada although only one school grade
was targeted [33, 39–43].
Race
Racial or ethnic identity was analysed in 31 studies from
the USA, Australia and Greece; 18 conducted multivari-
ate analyses. Analysis of >100,000 women in North Car-
olina adjusted for location, clinic, insurance, and age
found Black (aOR 0.55; 95 % CI 0.53–0.56), American
Indian or Alaskan (aOR 0.68; 0.61–0.77) and Hispanic
Electronic Database searches: Medline, Embase, Global Health, Popline, Web of Science,
Africa Portal, Africa-wide information, ADOLEC, Cochrane, Campbell, Open Grey, EthoS.
Institutional Library searches: PATH, GAVI, 3ie and WHO
(n = 11,856 records)
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Records after duplicates removed 
(n =6359)
Titles/ abstracts screened 
(n = 6359)
Excluded (n =5857) 
(Age range (<9 years), single 
dose vaccine or booster,
non-routine delivery,no data
on completion)
Full-text articles assessed for
eligibility (n =502)
English n=439, French n=31, 
Spanish n=32 
Full-text articles excluded 
(n =441)
(Age range (<9 years), single
dose vaccine or booster, 
non-routine delivery, no data
on completion) 
Studies assessing factors
influencing vaccine 
completion*
(n = 61 articles)
HPV (n=48)
Hep B (n=14)
Hep A(n=2)
Varicella (n=1)
Fig. 1 Systematic review flow diagram. Caption: the PRISMA flow diagram for the systematic review detailing the database searches, the number
of abstracts screened and the full texts retrieved. *Some articles analysed >1 vaccine
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion
Author; date Sample size Country; source of sample Year of data
collection
Vaccine Vaccine target
age group
Vaccine delivery
strategy
Completion rate Factors investigated to
influence completion
Bednarczyk, R;
et al. 2011
588 USA. New York state
University health clinics
and classrooms: self-report
questionnaire.
2010 HPV 11–12 (with catch up to 26) Available at routine
healthcare provider
79 % Qualitative interviews
Carlos, R;
et al. 2010
232 USA. Mailed questionnaire
to attendees of breast and
cervical cancer screening
clinics (maternal report).
2010 HPV 11–12 (with catch up to 26) Available at routine
healthcare provider
19 % Race
Cassidy, W;
Mahoney, F. 1995
654 USA. School and
administrative data.
1994-5 HBV School grades 6–8 School-based clinic 82 % Gender, race
Chao, C; Slezak,
J; et al. 2009
18,275 USA. Electronic health
records from KPSC managed
care organisation.
2006-8 HPV 9–26 Available at routine
healthcare provider
43 % Maternal characteristics:
history of at least 1 Pap
test in the past 3 years,
history of abnormal pap
test result, history of genital
warts/ other STIs, SES
(neighbourhood median
household income,
neighbourhood average
adult education)
Chao, C; Velicer,
C; et al. 2009
34,193 USA. Electronic health
records from KPSC
managed care organisation.
2006-8 HPV 9–26 Available at routine
healthcare provider
41 % age, race, socioeconomic
status (census block
neighbourhood statistics,
medicaid eligibility), provider
characteristics, health care
utilization, women's health
related conditions, chronic
illness
Chou, B;
et al. 2011
1413 USA. Electronic health
records from ambulatory
care clinics (4) associated
with a University.
2007-8 HPV 11–12 (with catch up to 26) Available at routine
healthcare provider
33 % Age, insurance (private/public),
provider characteristics
(location, practice type
(pediatrics, gynaecology or
family practice)), race (White,
African American, Hispanic).
Cleves, M. 1998 520 USA. Medical records. 1995-6 HBV 11–19 Available at routine
healthcare provider
33 % Age, race, insurance, sexual
activity, risk behaviour
(drug use)
Cook, R;
et al. 2010
11,986 USA. Medicaid
administrative data.
2006-8 HPV 9–20 Available at routine
healthcare provider
27 % Age, race, provider of first
shot, insurance (months of
medicaid enrollment),
sexual activity.
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Crosby, R;
et al. 2011
209 USA. University of Kentucky,
rural community college
and rural health clinic
attendees
2007-8 HPV 9–26 Available at routine
healthcare provider
56 % urban Geography (rural/urban
location)
10 % rural
Deeks, S;
Johnson,
I. 1998
39,935 Canada. Administrative
data from Health units (7),
Greater Toronto Area
1994-5 HBV School Grade 7 School-based
delivery
95 % School characteristics,
knowledge/ education/
mobilisation
Dempsey, A;
et al. 2010
2625 USA. Health records from
20 university-affiliated
health clinics, Michigan
2007-8 HPV 9–26 Available at routine
healthcare provider
15 % Age, insurance, race
Dempsey, A;
et al. 2012
1714 USA. Health records from
20 university-affiliated
health clinics, Michigan
2008-9 HPV 9–26 Available at routine
healthcare provider
53 % Age, insurance, race
Dorell, C;
et al. 2011
18,228 USA. Stratified, national,
probability sample of
households (NIS-teen
survey)
2008-10 HPV 9–26 Available at routine
healthcare provider
53 % Age, insurance, health care
utilization, household income,
maternal education level,
maternal age, maternal marital
status, race, geography/
location
Fournier, M;
et al. 2013
1404 USA. Electronic medical
records from 2 primary
care clinics
2007-12 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
40 % Insurance, race, health care
utilization (other vaccines)
Ganry, O;
et al. 2013
France. Electronic records
of the Regime General
Insurance (for workers),
the RSI (for self-employed)
and the RSA (agricultural
occupations)
2009-10 HPV 14 (with a catch up to 23) Available at routine
healthcare provider
39 % Age, insurance, provider
characteristics.
(recently revised to 11–14)
Gold, R;
et al. 2013
786 USA. Electronic medical
records from an integrated
managed care organisation
2008 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
Socioeconomic status; health
care utilization; provider
characteristics; vaccine delivery
concomitant with first dose;
experiences at the first visit,
challenges to making or
keeping the index
appointment; Knowledge
and attitudes about HPV;
adverse events.
Gold, R;
et al. 2011
450 USA. Administrative data
from 19 school-based
health centres
2007-8 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
51 % Age, race and insurance status
Gonzalez, I;
et al. 2002
79,357 USA. Electronic Data from
3 Health Management
Organisations
1998 HBV 11–12 Available at routine
healthcare provider
73 %, 67 %, 45 % Provider characteristics
(Health care organisation)
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Harper, D;
et al. 2013
2422 USA. Electronic records
from a safety net health
care system Kansas
2006-09 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
42 % Age, race, concomitant (visit
type for first dose)
Hirth, J;
et al. 2012
271,976 USA. Electronic records of a
private insurance company
2006-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
38 % Age, provider type, time
Kester, L;
et al. 2011
500 USA. Knowledge networks
coordinated survey
(nationally representative)
2010 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
81 % Race, insurance, maternal
education, maternal
relationship status, maternal
history of HPV related condition,
geography.
Kouyoumdjian,
F; Bailowitz,
A. 2011
18 USA. Baltimore city health
department self report
interviews
2007-9 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
9.80 % Geography (access), adverse
events, qualitative reasons
(convenience, knowledge,
pain/discomfort)
Ladner, J;
et al. 2012
87580 Multi-country (7 low
resource countries).
Administrative data from
Gardasil Access Programme
grantee countries
2009-11 HPV Bhutan, Bolivia, Haiti,
Nepal: 9–13
School based, health
centre based or
mixed strategies
Bhutan: 88 %, Bolivia:
96 %; Cambodia: 95 %;
Cameroon 83 %, Haiti 76 %,
Lesotho 93 %;
Nepal 99 %.
Delivery strategy (school-
based, health facility model,
mixed model)
Cambodia: 11–18
Cameroon: 9–18
Lesotho: 10–18
Lancman, H;
et al. 2000
3 centres USA. Administrative data
from 2 school based health
centres and one adolescent
health clinic
1997-98 HBV 11 and above Available at school
based health centres
and routine providers
24 %, 29 %, 76 % Health centre characteristics
Laz, T;
et al. 2012
11,277 USA. Household
questionnaire sent to
parents
2010 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
49 % Age, parental education,
insurance, race, parental
income.
Lions, C;
et al. 2013
105,327 France. National Insurance
Reimbursement database
2007-8 HPV 11–14 (catch up to 19) Available at routine
healthcare provider
64.10 % Age, insurance, geography,
medical utilization
Macdonald,
V; et al. 2007
2471 Australia. Health centre
records from a primary
health care centre, Sydney
(high risk population)
1992-2003 HBV High risk adolescent
of any age
Available at routine
healthcare provider
and specialist clinics
21 % Age, gender, race (aboriginal),
risk behaviour (IDU, sex worker,
hep.C status) length of contact
with the health centre,
accelerated versus normal
schedule.
Moore, G;
et al. 2010
209 USA. Medical records of
community health clinic
attendees
Unknown HPV 11–12 (catch up to 26) Available at routine
healthcare provider
28 % Attitudes and believes
including perceptions of
risk, peer experience of HPV
vaccine, experience of cancer
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Nelson, J C;
et al; 2009
590445 USA. Vaccine Safety
Datalink population (MCO
registry)
1996-2004 Varicella,
HAV,
HBV
9–17 Available at routine
healthcare provider
Varicella: 35.9 %; HAV:
48.4 % (age 9–12), 40.3 %
(age 13–17); HBV: 63.4 %
(age 9–12), 45.1 % (age
13–17).
Age, provider site, gender,
length of MCO enrollment,
year of first dose, utilization of
medical visits in year prior to
dose 1
Sinka, K; et al.
2014
86769 UK. The Child Health System
database and the Scottish
Immunisation Recall System
2008-11 HPV 12–13 (catch up for 13–17) School-based (catch
up included supply
of vaccine at
primary health care)
Year 1: 89.4 % Scottish Index of Multiple
Deprivation (SIMD)
Year 2: 86.9 %
Year 3: 81 %
Markovitz, A; et
al. 2014
13,709 USA. Immunization registry,
Michigan residents
continuously enrolled
with a PPO
2006-11 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
22 % Maternal preventive care
utilization (Pap testing,
mammograms, primary
care office visits), age, race,
household education,
household income, maternal
age.
Middleman,
A. 2004
11,500 USA. School data 1998-2000 HBV School grades 5–6 School-based 72 % Insurance, race and gender
Middleman,
A B; et al. 1996
826 USA. Medical records from
an adolescent health clinic
Unknown HBV Any adolescent
attending the
clinic
Available at routine
healthcare provider
23 % Socio-demographics, risk
behaviors (for hepatitis B),
medication use, chronic
illnesses, and experience,
knowledge and attitudes
about hepatitis B and the
immunization
Middleman,
A B; et al. 1999
943 USA. Questionnaires
distributed at hospital
and school based clinics
1994-5 HBV Any adolescent
attending the
clinics
Available at routine
healthcare provider
and school based
clinic
47.6 % (Clinic); 41.7 %
(School-based clinic)
Race, insurance, residential
zip code, risk factors for
acquiring hepatitis B, risk
behaviors (cigarette and
substance use), and academic
achievement, chronic illness,
healthcare utilization,
knowledge about hepatitis
B and the vaccination, family
history of hepatitis B
vaccination, travel time,
and mode of transportation
to the clinic.
Monnat, S;
Wallington, S.
2013
4,776 USA. Behavioral Risk Factor
Surveillance System Survey
data in 10 territories
2008-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
14 % Mother’s history of cervical
screening (Pap test).
MooreCaldwell,
S; et al. 1997
174 USA. Medical records from
a university adolescent
clinic and junior-senior
private high school clinic
1992-3 HBV Any adolescent
attending the
clinics
Available at routine
healthcare provider
at school based
clinics
89 % Adolescent and parent
knowledge of hepatitis B,
perceived risk.
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Moss, J L;
et al. 2013
105,121 USA. North Carolina
Immunization Registry
Not
available
HPV 11–12 (catch up to 26) Available at routine
healthcare provider
28 % Gender ratio, race, provider
specialty and adolescent
patient load, reminder/
recall system, time to
documentation in NCIR,
computers per clinic, age
of vaccine recommendation
(Tdap, Meningococcal, HPV)
Musto, R;
et al. 2013
35,592 Canada. Calgary zone
Public Health vaccination
database
2008-11 HPV Grades 5 and 9 School-based
programme and
available at
community public
health clinics
75 % (School-based); In-school vs community
health clinic delivery model,
socioeconomic status, school
provider type, history of HBV.
36 % (community)
Neubrand, T;
et al. 2009
352 USA. Medical records
review from two different
sites
2007-8 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
58 % Age, race, insurance (private
vs Medicaid/Child Health
Insurance Program [CHIP]),
and distance from home to
the clinic, sexual activity prior
to initiation of the series,
history of an STI, cervical
screening history within 3
years of vaccine initiation,
reason for clinic visit
Niccolai, L;
et al. 2011
7606 USA. NIS-Teen survey:
Random digit dialing
household survey.
2008-9 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
55 % Race, socioeconomic status,
age, maternal characteristics,
insurance, healthcare
utilization, geography
(region) and year.
Perkins, R B;
et al. 2012
7702 USA. Electronic medical
records from Boston
Medical/ community
health centers
2007-8 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
20 % Age, location, number of
clinic visits in study period,
race, risk behaviour
(documentation of STI or
alcohol use), history of
meningococcal or tdap
booster vaccine.
Pruitt, C N;
et al. 2013
978 USA. Rochester Epidemiology
Project records (REP) from
medical records
2006-9 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
Somali girls: 52 %;
white/non-Hispanic:
72 %
Somali ethnicity
Rahman,
et al. 2013
2632 USA. Data from Behavioral
Risk Factor Surveillance
System Telephone survey
2008-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
17 % Geography/ location
Reiter, P L;
et al. 2009
229 USA. Telephone survey,
North Carolina.
2007-8 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
83 % Adverse events/ reported
pain from HPV vaccination
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Reiter, P;
et al. 2013
1951 USA. NIS-Teen survey:
Random digit telephone
survey
2008-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
28 % Age, race, healthcare utilization
in last year, insurance,
maternal characteristics,
knowledge of HPV, provider
recommendation,
socioeconomic status.
Rouzier, R;
Giordanella,
J. 2010
77,744 France. CPAM social
security database
2007-8 HPV 14 (Catch up to 23) Available at routine
healthcare provider
43 % Age, provider (general
practitioner vs. gynecologist)
Rubin, R;
et al. 2012
10,821 USA, Administrative
reimbursement data and
medical records from
medical group practices
2006-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
27 % Pre-existing STD, age, provider
medical department
Sakou, I I;
et al. 2011
1005 Greece. Convenience sample
of Adolescent Health Unit
attendees
2009 HBV,
HAV,
HPV
HPV: 12–15; HAV,
HBV: catch up 11–18
Available at routine
healthcare provider
Not reported Gender, race/ nationality,
parental education, family
status
Schluterman,
N H; et al. 2011
8069 USA. Database of the
University of Maryland
Medical Center (UMMC)
2006-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
11 % Race, insurance status
(publicly funded, private,
or none), age (9–13, 14–17,
or 18–26 years), and place
of residence (urban or
suburban Baltimore).
Schmidt, M
A; et al. 2013
311213 USA. Administrative data
from vaccination sites
2006-11 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
42 % Age, calendar year
Schmitt, K;
Thompson,
D. 2013
n/a USA. Statewide
Immunization Registry
2001-11 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
52 % Age, insurance, provider
type, race
Seid, M;
et al. 2001
800 USA. Survey to parents of
children at 5 Schools,
San Diego
1998 HBV 11–12 Available at routine
healthcare provider
27 % Provider, school based
clinics, school socioeconomic
status, home language, race,
insurance, health care
utilization, heard about
mandatory vaccination
from health care provider.
Smith, L M;
et al. 2011
2519 Canada. Universal health
insurance program database.
2007-10 HPV School grade 8 School-based 86 % Age, parental income, and
place of residence, vaccination
history, health services
utilisation, medical history.
Tan, W;
et al. 2011
138823 USA. NCIR immunisation
registry
2006-2009 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
55 % Race, age, county of residence,
provider clinic type, insurance.
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Table 3 Summary of included studies. Caption: a summary of the studies included in the review, including details of sample size, the source of the sample, year of data
collection, vaccine investigated, target age group, delivery strategy, completion rate attained and factors investigated to influence completion (Continued)
Teplow-Phipps,
R; et al. 2014
1,494767 USA. Citywide Immunization
Registry (CIR), New York City
2005-12 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
38.4 % (females) Age, gender, insurance, clinic
specific variables: provider
practice-type, number of
Tdap vaccines reported
(proxy for practice size),
and socioeconomic status
of practice location.
35.7 % (males)
Tracy, J K;
et al. 2010
9658 USA. Clinical data repository
at the University of Maryland
Medical Center
2006-10 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
31 % Age, race.
Tung, C S;
Middleman,
A B. 2005
8918 USA, Data from 75 schools
participating in HBII (Hep
B immunization initiative).
1999-2000 HBV 13–15 School-based 59 % Publicity/promotion, packet
distribution, return of forms,
ratio of students to clinic,
provider characteristics
Verdenius, I;
et al. 2013
1563 USA. Electronic medical
records
2006-9 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
32 % Age, type of health visit,
healthcare utilization,
concomitant healthcare
delivery.
Widdice, L E;
et al. 2011
3297 USA. Review of medical
records from academic
medical center
2006-8 HPV 11–12 (catch up to 26) Available at routine
healthcare provider
28 % Age, race, insurance,
healthcare utilization (DMPA),
clinic location, time period o
f vaccine series initiation
LaMontagne,
D; et al. 2011
7269 Peru, India, Uganda,
Vietnam. Population based
household survey
2008-10 HPV Peru: grade 5; Uganda:
grade 5 or age 10;
Vietnam: grade 6 or
age 11; India: 10–14.
School-based or
health centre based
in all 4 countries
Not reported Delivery Strategy
G
allagher
et
al.BM
C
Public
H
ealth
 (2016) 16:172 
Page
11
of
17
(aOR 0.75; 0.72–0.79) women had 25–45 % lower likeli-
hood of completion compared to White women [43].
Race was the only significant predictor of completion in
the NIS-Teen household survey in USA [44]. Ten add-
itional large database studies in the USA with multivari-
ate analyses corroborate this association for both HPV
and HBV vaccines [15, 16, 36, 37, 39, 40, 42, 43, 46–48].
However, no association between race and completion
was found in 5 studies when controlling for gender, insur-
ance and health clinic characteristics [29, 38, 45, 49, 50].
Hispanic adolescents were underrepresented in one survey
with a low response rate [29].
Greek non-nationals had lower completion rates
(33 %) than nationals (60 %) for 2 doses of HAV [51]. In
the northern territories of Australia, 3 dose coverage of
HPV vaccine was lower in indigenous compared to non-
indigenous groups (54 % vs. 64 %), but completion rates
were the same (84 %) [52].
Insurance
Many countries have supplied HPV vaccine free-of-
charge. In the USA, although the vaccine was not initially
eligible for reimbursement in some health insurance plans,
after it was recommended by the Advisory Committee on
Immunization Practices it was included in the Vaccines
for Children (VFC) programme which provides for under-
insured and uninsured children [1]. Insurance status was
investigated as a risk factor in 25 articles, 16 conducted
multivariate analyses (15 USA, 1 France). In 2011, insur-
ance status remained a significant predictor of HPV series
completion in the USA; those publicly insured (Medicaid)
were 2.08 times (95 % CI 1.16–3.7) more likely to
complete compared to those with no insurance; those pri-
vately insured were not significantly more likely to
complete than those on public insurance (aOR 1.16;
95 % CI 0.97–1.38) controlling for age, race, contra-
ception use [42]. The association between insurance
status and completion was stronger in 2006–8 reflect-
ing policy changes [16, 43]. In France completion
rates were lower among recipients of complimentary
social welfare compared to those with private insur-
ance (aRR 0.88; 95 % CI 0.83–0.93) [34].
Longer enrolment on an insurance plan (>12 years) was
associated with a 1–14 % increase in likelihood of comple-
tion of 2 doses of varicella vaccine; 9–12 % increased like-
lihood for HAV and 21–23 % for HBV in the vaccine
safety database of almost 600,000 people in the USA be-
tween 1998 and 2004 [31] controlling for age, gender,
healthcare utilisation and provider characteristics.
Across the USA there are substantial differences
across states in beliefs, policy, and the rapidity of im-
plementation of changes made at the national level.
In Oregon state in 2008, HPV vaccine was offered
free of charge and no difference was found in com-
pletion rates between publicly and privately insured
participants [53]. In Maryland in 2006–10 private in-
surance was found to be a risk factor for non-
completion compared to those publicly insured (aOR
0.76; 95 % CI 0.59–0.98), controlling for race and age
[37]. No association in multivariate analyses was seen
in 5 studies in the USA [29, 39, 40, 44, 50].
Gender
Gender was assessed in seven articles; no correlation be-
tween completion of HBV and gender was seen in un-
adjusted results from Greece [51], nor in adjusted
results in Australia [35]. In the USA, controlling for de-
livery site, age, insurance, year, chronic conditions and
Table 4 Data available on factors investigated across countries and vaccines
Factor investigated Countries (Number of studies
with multivariate analyses)
Vaccine
HPV HBV HAV Varicella
Age USA (17), Canada (1), France (1), Australia (1) ✓
Race USA (16), Australia (1), Greece (1) ✓ ✓ ✓
Insurance USA (15), France (1) ✓ ✓ ✓ ✓
Gender Australia (1), USA (2) ✓ ✓
Socio-economic status USA (11), Canada (1), UK (1), France (1) ✓ ✓
Healthcare utilization USA (14), France (1), Australia (1), Canada (1) ✓ ✓ ✓
Vaccine knowledge USA (3) ✓ ✓
Adverse events USA (3) ✓
Risk behaviour USA (3), Australia (1) ✓ ✓
Concomitant healthcare USA (3) ✓
Access USA (2) ✓ ✓
Maternal characteristics Pap smear history – USA (3) ✓ ✓
Education – USA (7), Greece (1)
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prior healthcare utilization, male gender was marginally
associated with lower completion for varicella (aOR
0.93; 95 % CI 0.90–0.96), HAV (aOR 0.98; 0.97–0.99)
and HBV (aOR 0.97; 0.96–0.98) [31]. Included studies
did not report completion of HPV vaccine in boys, rec-
ommendations to vaccinate boys were issued in 2015 in
the USA; however, clinics in the USA with higher fema-
le:male ratios obtained higher completion rates of HPV
vaccine among females (aRR 2.16; 1.13–4.13) [49].
Socio-economic status
Socio-economic status (SES) was analysed in studies in
the USA (n = 14), Canada (n = 2), UK (n = 1) and France
(n = 1); 14 conducted multivariate analysis. Median
neighbourhood income and average adult education
[54], parental income levels [39, 50, 55], household in-
come [56] and poverty status [45] were not associated
with completion in multivariate analyses.
Every 10,000USD rise in median neighbourhood in-
come was associated with a 15 % increase in HBV
completion (aRR 1.15; 95 % CI 1.06–1.25) [47] and a
1 % increased likelihood of HPV completion in 20,000
9–17 year old American girls (aRR 1.01; 1.01–1.02)
[57]. Average census block education level was posi-
tively associated at a similar magnitude of effect (aRR
1.03; 1.02–1.05) [57]. Adolescent girls living below the fed-
eral poverty level were signifıcantly less likely to complete
vaccination compared to adolescents with household in-
comes > $75,000 (aOR 0.76; 0.63–0.92) [44].
The effect of SES may differ by delivery strategy; in
Canadian public schools with in-school HPV vaccine
delivery, completion increased as SES decreased, in
Catholic schools in which the pupils relied on com-
munity delivery, completion decreased as SES de-
creased [58]. A linear trend with the Scottish multiple
index of deprivation was found with completion but
not with initiation; however, the difference between
the most and least deprived groups was small (8 %)
and disappeared with the administration of a catch-up
dose 1 year later [59]. Girls in Canada in 2007–8 living in
lower income neighbourhoods were significantly less likely
to complete HPV vaccine than girls living in middle
income neighbourhoods (aOR 0.45; 0.28–0.72) [33]. In
France compliance with the HPV vaccine schedule was
lower in social welfare recipients compared to non-
recipients (aRR 0.88, 0.83–0.93) [34].
Healthcare utilization
History of health care utilization was inconsistently asso-
ciated with completion. Seventeen articles from the
USA, France and Australia analysed an individual’s prior
use of health care (defined by receipt of other recom-
mended vaccines, or the number of prior visits to a
primary health care provider) and completion of a
multi-dose series of varicella, HPV or HBV vaccines.
In adjusted analyses in the USA, >10 visits to a
health care provider in the last year was associated
with 15 % increased likelihood of HPV vaccine com-
pletion and a 4–6 % increase in HBV completion
[31]. Similar findings were reported in France where
compliance with the HPV vaccine regimen was 10 %
higher if a girl had >6 consultations with a family
physician in the past year [34]. The magnitude of the
effect is supported by reports of a 2 % increased like-
lihood of completing the HPV vaccine series with
every primary care provider visit in the past year [36].
A further eight studies found no association between
vaccine completion and the number of visits to a pri-
mary healthcare in the preceding 2 years [60], non-acute
care in the year preceding initiation [29, 33, 39, 44, 55],
previous prescriptions [47] or receipt of tetanus, diph-
theria, and pertussis booster (Tdap) and meningococcal
vaccines [38].
Recorded contraceptive use (DMPA) at any time in
the medical records by HPV vaccine recipients was asso-
ciated with a two-fold increase (95 % CI 1.72–2.47) in
the odds of HPV vaccine completion [42]. In Canada,
HBV vaccination conferred 16.9 times higher odds (95 %
CI 14.8–19.2) for HPV vaccine completion in compari-
son with those who had not received HBV. However, the
association could be confounded by the differing vaccin-
ation policies and delivery strategies by school [58]. In
Australia in an area with a high risk population, includ-
ing young sex workers and drug users, a shorter time
interval (<2 weeks) between first contact with the health
care provider and initiation of vaccine series correlated
with better HBV completion [35].
Vaccine related knowledge
Three American studies examined knowledge in relation
to completion in multivariate analysis [45, 47, 55]. The
ability to correctly identify the number of required doses
remained associated with series completion (aRR 1.38;
95 % CI 1.08–1.76) [55]. Parents who remember receiv-
ing a provider recommendation for vaccination were
more likely to have daughters who had completed the
regimen (aOR 2.71; 1.99–3.70) [45]. However, general
knowledge of HPV and HBV vaccine was not associated
with completion in adjusted analyses [45, 47].
Adverse events
Three studies assessed whether experience of adverse
events following HPV vaccination affected series com-
pletion in the USA. Parents of daughters who had com-
pleted the three dose series reported pain or discomfort
as often as parents whose daughters were late for their
second or third dose (OR 0.76; 95 % CI 0.33–1.77) [61].
In a survey of over 3000 vaccine recipients [55]
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(response rate 27 %), multivariate analysis controlling
for age, socio-economic status, health care utilization,
showed reports of bruising or swelling at first dose
did not affect completion of the series (aRR 0.88;
0.7–1.00). An association was not apparent for those
reporting pain, syncope or dizziness [55]. A qualita-
tive study of 18 women in the USA who did not
complete the HPV vaccine series found none of them
mentioned adverse events as a reason [62].
Risk behaviour
A variety of risk behaviours in seven studies were
assessed in relation to completion of HBV or HPV vac-
cine schedules; no associations were found. Drug use,
history of sexually transmitted infections (STIs), or alco-
hol use was not associated with completion in the USA
[38, 47, 63]. In multivariate analysis in Australia, intra-
venous drug use, sex work, or hepatitis C status did not
correlate with likelihood of completion of HPV in a
health unit serving at-risk populations [35].
Concomittant healthcare
Three articles assessed the effect of concomitant
health service delivery on adherence to HPV in the
USA. Receipt of another vaccine at the time of HPV
vaccination was not associated with odds of HPV
completion controlling for socio-demographic and
provider characteristics [55]. However, if the first dose
was given at a health care provider visit which was
attended primarily for another reason other than
HPV, the odds of a mistimed 3rd dose were almost
double (aOR 1.97; 95 % CI 1.39–2.80) than that if the
first dose was at a vaccine only visit, controlling for
age and race [48]. Type of visit was not associated in
analysis investigating the effect of age and healthcare
utilization [41].
Access
Access to vaccination sites was assessed in two stud-
ies in the USA. Compliance to the schedule and com-
pletion of the series were not governed by proximity
or mode of transportation to the clinical site [47].
Distance from home to clinic was not associated with
completion controlling for age, race, and healthcare
utilization [40].
Qualitative studies
One qualitative study investigated why 9–26 year olds
did not return for the final dose of the HPV vaccine
series, in non-exclusive responses: 33 % claimed they
didn’t know they were meant to obtain further doses,
23 % claimed they were too busy, 15 % cited inconveni-
ence, 38.5 % claimed they were too busy or forgot, 7.7 %
claimed they were too busy and times were inconvenient
[62]. Two additional surveys of partially vaccinated uni-
versity students in the USA and Australia indicated the
potential problems with vaccinating older age groups
who have competing priorities; reasons focused on in-
convenience and lack of time [64, 65].
Maternal characteristics
Three studies in the USA analyzed the relationship be-
tween maternal preventative behavior (cervical screening)
and their daughter’s HPV vaccine series completion. In
multivariate analysis, controlling for demographic, socio-
economic, family, and health plan characteristics, all three
studies found that girls whose mothers had received a pap
smear in the past three years were more likely to complete
the HPV vaccine series (aOR 1.07, 95 % CI 1.06–1.08)
[56]; 1.42, 1.31–1.54 [54] and 1.87, 1.31–2.75 [66]).
The relationship between maternal education and vac-
cine series completion was assessed in eight studies con-
ducted in the USA (n = 7) and in Greece [51].
Adolescents whose mothers had less than high school
education were less likely to complete the vaccine series
in multivariate analysis [44, 66]; both studies controlled
for adolescent age, SES, and mother’s health characteris-
tics and found similar effect estimates (aOR 0.68; 95 %
CI 0.56–0.84) [44]; aOR 0.60; 0.41–0.87 [66]). No associ-
ation between maternal education and HPV or HAV
vaccine series completion in multivariate analysis was
found in three studies [39, 45, 50].
Maternal age and marital status were found to have no
or very slight associations with vaccine series completion
in four of the five included studies [39, 44, 45, 66]. In
unadjusted analysis, one study found daughters with
mothers aged over 40 years were more likely to complete
the HPV vaccine series compared to mothers who were
less than 40 years old [56].
Provider/ organisational characteristics
Delivery model
There is strong evidence for high completion rates with
school-delivery in high - income and low-middle income
countries. Canadian in-school HPV vaccination comple-
tion rates were 75 % (95 % CI 74.7–75.8) compared to
36 % (95 % CI 35.3–37.2) for girls provided with a
community-delivery model [58]. In-school vaccinations
conferred 1.8 times the odds of completing the HBV series
compared to if adolescents had to go off-site (95 % CI
1.15–2.8) in a parent survey in the USA controlling for
age, race, insurance, SES, prior healthcare utilization [29].
Only 2 articles included data from low and middle -
income countries (LMIC); descriptive results are avail-
able regarding the success of different delivery strategies
[67]. In Uganda, a school-based strategy appeared more
successful (94 % completion) than a strategy in which
the vaccine was given in the community with a child
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health programme (79–87 % completion year 1-year 2)
although the delivery strategies had slightly different tar-
get populations. Peru’s school-based strategy achieved
98.7 % completion, whilst combined school-based and
health centre strategies in Vietnam achieved >99 % com-
pletion. In India, very similar completion rates were
achieved in campaign and routine delivery approaches
(97–98 %) [67]. Differences in completion rates achieved
in 21 demonstration projects in 14 countries implement-
ing different models of delivery were insignificant [68];
however, the mixed model (school based delivery with
mop-up activities at health centres) seemed to confer
marginally higher completion (96.6 %), the school-only
model was intermediate (88.6 %) and the health facility-
only model was least effective (79.7 %)(p = 0.39) [69].
In Australia, high-risk groups, benefited from an accel-
erated schedule (0, 7, 21 days and 12 months), which in-
creased the likelihood of HBV vaccine completion 1.35
times (1.01–1.80) controlling for drug use, and length of
contact with the health facility [35].
Provider characteristics
Vaccine schedule completion was higher in an American
school based programme when students returned the
consent forms to their teacher compared to the school
nurse [70]. In 1994–5 in Canada, initial parental consent
was lower at private schools compared to public schools;
however, private and public schools did not differ in
completion rates. Different education providers (teachers
or public health nurses) did not have an effect on com-
pletion, although education from teachers was associated
with higher consent [30].
A further 17 studies investigated health provider char-
acteristics, of which 12 reported adjusted analyses. There
was no evidence that the speciality of an adolescent girl’s
primary care physician influenced HPV series comple-
tion in multivariate analyses [15, 16, 36, 42, 49, 55].
However, for women >17 years of age in the USA, those
with a paediatric/internal medicine physician were slightly
less likely to complete the HPV regimen than those with a
family medicine physician. Female providers were not sig-
nificantly associated with completion (male primary care
provider aRR0.93 0.85–1.01) [36]. In an American datalink
study, those vaccinated at paediatric clinics had the high-
est completion (61 %) compared to family care practices
(53 %; aOR 0.78; 95 % CI 0.76–0.80) and the local health
departments (39 %; aOR 0.48; 0.47–0.50) [43].
Discussion
We present a comprehensive review of the available lit-
erature on factors influencing adherence to multi-dose
vaccine schedules among adolescents. The majority of
studies took place in the USA (n = 49), the remainder in-
cluded Canada (n = 3), France (n = 3), Australia (n = 2),
Greece (n = 1), the UK (n = 1) and 2 multi-country
studies including LMICs. The two studies including
LMICs focused on organisational level factors and re-
ported high adherence to HPV vaccine [68], therefore
our summaries of individual level factors are limited
in generalizability to developed settings. The high
level of variation in the definitions, number and se-
lection of factors investigated in each study limits the
comparability of study results and prevented conduct
of a meta-analysis. The overall impact of the identi-
fied characteristics on vaccine adherence is likely to
be dependent on the mix of other factors present, as
well as the programmatic and local context.
Good adherence to multi-dose vaccines appears to be
higher in early adolescence (9–12 year olds) when com-
pared to later adolescence (>14 years old). It is unclear
whether this is linked to adolescent health seeking be-
haviour, which was inconsistently associated with com-
pletion, or whether it is governed by logistical reasons as
cited in qualitative results. It could reflect factors which
are not explored in the available literature such as which
groups were most targeted with communication mate-
rials or the general decrease in utilization of health ser-
vices through adolescence [71]. In some populations in
the USA, there is evidence that Black or Hispanic girls
are disproportionately prone to low completion rates
when compared to White girls after adjustment for so-
cioeconomic status and insurance, despite some reports
of similar rates of initiation. Adolescent females may
have a slightly elevated likelihood of vaccine completion
compared to males; this association may be a symptom
of increased opportunity whilst accessing contraception
at the health centre. Higher household income, maternal
education and maternal preventative health behaviour
were associated with higher completion rates when com-
pared to lower socio-economic families and those
mothers who rarely sought screening. Insurance status
may have a decreasing effect on completion over time as
knowledge spreads that both HBV and HPV vaccines are
eligible for reimbursement on any insurance plan in the
USA. Experience of adverse events and general know-
ledge about the vaccine did not affect completion rates.
School-based delivery alongside supplying vaccine to
health centres for out-of-school girls appears to be a
successful approach in countries with relatively high
school attendance, including some LMICs [69], the UK
[59] and Canada [58].
Conclusions
The factors which affect rates of vaccine completion are
context and time specific. Providers and programme
planners should be aware that obtaining good consent
and initiation rates is not enough; sub-groups within the
population may need more help than others to complete
Gallagher et al. BMC Public Health  (2016) 16:172 Page 15 of 17
the series. Efforts need to continue past the first dose to
reduce inequality in completion. Adolescents captured
for the first dose remain only partially protected from
vaccine related disease until receipt of the final dose of
the schedule.
Opportunistic vaccination at the delivery point of
other services should be utilized as a strategy to increase
vaccine completion. There is no evidence that concomi-
tant service delivery is associated with lower completion.
Among 11–18 year olds in Seattle, 71 % of visits to a
primary health practitioner in 2006–11 were found to be
lost opportunities for dose 3 of HPV vaccine [72]. Espe-
cially utilizing visits which were not originally for pre-
ventative health care services could rapidly improve
completion rates and access those adolescents with low
healthcare utilization [71, 72].
A Cochrane review in 2005 found 47 articles detailing
the effect of patient reminder/recall on vaccine uptake,
all were conducted in developed countries, only one
study was conducted in adolescents [73]. In pooled re-
sults across all age groups, all reminder/recall systems
appeared to improve coverage compared to the control
groups. Personal telephone reminders were the most ef-
fective intervention (OR 1.92; 95 % CI 1.2–3.07). Letter
reminders were close to the effectiveness of phone re-
minders (OR 1.79; 1.5–2.15), a postcard alone was less
effective (OR 1.44; 1.09–1.89), and automated phone
calls were least effective (OR 1.29; 1.09–1.53). Interven-
tions to improve completion of vaccine series need to be
assessed and the use of novel technologies needs to be
explored where electronic records and recall systems are
not available.
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